Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

The researchers conducted a double-blind, randomized, placebo-controlled trial involving 2,655 adults in 30 countries around the world. The study participants were suffering from primary or recurrent ...

— Greg Vigna, M.D., J.D. SANTA BARBARA, CA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- “Prolonged IV antibiotics are necessary for the treatment of Grade ...

The procedure involves transplanting a stool sample from a healthy donor to treat C. difficile. One-quarter of patients who contract a C. difficile infection will have a recurrence, and those who do ...

The panelist discusses how recurrent Clostridioides difficile infections represent a critical health care challenge, characterized by unmet needs in long-term prevention, microbiome restoration, and ...

Please provide your email address to receive an email when new articles are posted on . Treatment-emergent adverse events occurred in 66.4% of patients who received Rebyota vs. 60.2% on placebo. Most ...

C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

People with pneumonia who have experienced Clostridioides difficile (C. diff) infections may be able to reduce recurrences if they take doxycycline instead of the standard treatment. The study comes ...

Please provide your email address to receive an email when new articles are posted on . Ninety-five percent of patients achieved treatment success at 8 weeks after administration of Rebyota via ...